News

Ligand Pharmaceuticals Spins Off Pelican Technology Holdings and Merges with Primordial Genetics

1 Mins read

Ligand Pharmaceuticals recently announced its decision to spin off its subsidiary, Pelican Technology Holdings, and merge it with Primordial Genetics. The newly formed private company, called Primrose Bio, will primarily focus on the field of synthetic biology.

As part of the deal, Ligand will maintain ownership of the existing commercial royalties associated with the Pelican Expression Technology and hold a 49.9% stake in the merged entity.

In addition to this, Ligand will be contributing $15 million to Primrose Bio in exchange for a portion of the economic rights to certain products. While this divestiture will result in lower contract revenue for Ligand in the current year, it is expected to have a positive impact on the company’s adjusted earnings.

Ligand’s full-year revenue forecast now stands at $124 million to $126 million, as compared to the previous guidance of $124 million to $128 million. The company also anticipates adjusted earnings per share for the full year to be in the range of $5.10 to $5.25, surpassing the previous forecast of $4.85 to $5.

Related posts
News

Semler Scientific Amplifies Bitcoin Investments, Solidifying Its Position in Digital Assets

1 Mins read
Semler’s strategic direction offers insights for other institutional investors. U.S.-based medical technology company Semler Scientific has captured attention in the cryptocurrency realm…
News

IMF commends Sri Lanka's new govt for reform continuation

1 Mins read
COLOMBO, Apr 25: The International Monetary Fund (IMF) on Friday commended the Sri Lankan government, led by President Anura Kumara Dissanayake, for…
News

U.S. Federal Reserve revokes crypto guidance for banks

1 Mins read
25th April 2025 – (Washington) The U.S. Federal Reserve announced on 24th April that it will withdraw previous guidance requiring state member…

Leave a Reply

Your email address will not be published. Required fields are marked *